VTYX popping 31% today. Strong earnings report, and positive trial results.

Shares of Ventyx Biosciences Inc (VTYX) are trading 31% higher at a price of $24.28 at the time of this writing. The stock is moving on strong earnings reports of EPS of -$0.39, beating analyst estimates by $0.06 and that it's leading drug candidate had performed well in a phase 1 trial.

Ventyx Biosciences Inc has been trading between a 52-week high of $26 and a 52-week low of $9.5. The stock has a market cap of $1.23 Billion.

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.